AA
ANIP icon

AlphaMark Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

AlphaMark Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-11,100
Closed -$741K – 513
2018
Q2 		$741K Buy
11,100
+6,900
+164% +$431K 0.3% 72
2018
Q1 		$245K Buy
+4,200
New +$267K 0.1% 105

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AlphaMark Advisors's ANIP Position: Q3 2018 in Review

AlphaMark Advisors sold out of ANI Pharmaceuticals (ANIP) in Q3 2018, closing a stake of 11,100 shares — an estimated $741K sold.

AlphaMark Advisors first reported a position in ANIP in Q1 2018 and held it in 2 quarters. The position peaked at $741K in Q2 2018. 173 funds tracked by Wall St. Rank hold ANIP as of Q3 2018.

  • AlphaMark Advisors reported no remaining ANI Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • AlphaMark Advisors sold 11,100 ANI Pharmaceuticals shares in Q3 2018, an estimated $741K.
  • AlphaMark Advisors first reported a position in ANI Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • AlphaMark Advisors's ANI Pharmaceuticals position peaked at $741K in Q2 2018.
  • 173 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2018.

Based on AlphaMark Advisors's 13F filing for Q3 2018, filed 5 Nov 2018.